PITTSBURGH, Dec. 29, 2021 /PRNewswire/ -- Viatris Inc.
(NASDAQ: VTRS) announced that it is pleased with decisions issued
today which affirm the U.S. Patent and Trademark Appeal Board's
prior rulings that found the challenged claims of Sanofi's Lantus®
SoloSTAR® device patents, U.S. Patent Nos. 9,603,044, 8,992,486,
9,526,844, 9,604,008, and 8,679,069, unpatentable.
These affirmances reinforce the company's continuing efforts to
break down barriers to patient access for important medicines such
as Semglee® through its Global Healthcare Gateway®. Viatris and
Biocon Biologics Ltd. launched their interchangeable Semglee®
products (insulin glargine-yfgn) last month, which are the first,
and currently the only, interchangeable biosimilars to Lantus®,
providing more affordable options for the millions of Americans
living with diabetes.
The Semglee® products are available in vial and prefilled pen
presentations and are interchangeable for the reference brand,
Lantus®, allowing for substitution at the pharmacy counter.
Semglee® is indicated to help control high blood sugar in adult and
pediatric patients with type 1 diabetes and adults with type 2
diabetes.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare
company, empowering people worldwide to live healthier at every
stage of life. We provide access to medicines, advance sustainable
operations, develop innovative solutions and leverage our
collective expertise to connect more people to more products
and services through our one-of-a-kind Global Healthcare Gateway®.
Formed in November 2020, Viatris
brings together scientific, manufacturing and distribution
expertise with proven regulatory, medical and commercial
capabilities to deliver high-quality medicines to patients in more
than 165 countries and territories. Viatris' portfolio comprises
more than 1,400 approved molecules across a wide range of
therapeutic areas, spanning both non-communicable and infectious
diseases, including globally recognized brands, complex generic and
branded medicines, a growing portfolio of biosimilars and a variety
of over-the-counter consumer products. With a global workforce of
approximately 38,000, Viatris is headquartered in the
U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
Twitter at @ViatrisInc, LinkedIn and YouTube.
Forward-Looking Statements
This press release includes statements that constitute
"forward-looking statements." These statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward looking statements may include
statements about the outcome and status of ongoing litigation.
Because forward-looking statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such statements. Factors that could
cause or contribute to such differences include, but are not
limited to: the scope, timing and outcome of any ongoing legal
proceedings and the impact of any such proceedings; that court
decisions are not yet final and are subject to further review,
rehearing and appeal, which could result in an adverse outcome; the
potential impact of public health outbreaks, epidemics and
pandemics, including the ongoing challenges and uncertainties posed
by the COVID-19 pandemic; the integration of Mylan N.V. and Pfizer
Inc.'s Upjohn business (the "Upjohn Business"), which combined to
form Viatris (the "Combination") and the implementation of our
global restructuring initiatives being more difficult, time
consuming or costly than expected, or being unsuccessful; the
ability to achieve expected benefits, synergies and operating
efficiencies in connection with the Combination or its
restructuring initiatives within the expected timeframe or at all;
actions and decisions of healthcare and pharmaceutical regulators;
changes in healthcare and pharmaceutical laws and regulations in
the U.S. and abroad; any regulatory, legal or other impediments to
Viatris' ability to bring new products to market, including but not
limited to "at-risk" launches; Viatris' or its partners' ability to
develop, manufacture and commercialize products; any significant
breach of data security or data privacy or disruptions to our
information technology systems; risks associated with international
operations, including our operations in China; the ability to protect intellectual
property and preserve intellectual property rights; changes in
third-party relationships; the effect of any changes in Viatris' or
its partners' customer and supplier relationships and customer
purchasing patterns; the impacts of competition; changes in the
economic and financial conditions of Viatris or its partners;
uncertainties and matters beyond the control of management; and the
other risks Viatris' filings with the Securities and Exchange
Commission. Viatris routinely uses its website as a means of
disclosing material information to the public in a broad,
non-exclusionary manner for purposes of the SEC's Regulation Fair
Disclosure (Reg FD). Viatris undertakes no obligation to update
these statements for revisions or changes after the date of this
release other than as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viatris-wins-court-decisions-on-sanofi-appeals-of-lantus-patent-invalidations-301451703.html
SOURCE Viatris Inc.